Physician profile
Adam S Kanter
NPI 1770791709
$2,553,432.49
in general payments reported to CMS, 2019-2025
32 companies · $501K in 2025
The $501K reported for 2025 was more than what 99% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358K · 2020: $691K · 2021: $385K · 2022: $306K · 2023: $225K · 2024: $88K · 2025: $501K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $361K · Consulting Fee: $268K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $175K · Travel and Lodging: $5,834 · Food and Beverage: $4,613 · Entertainment: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $360,503.80 |
| Consulting Fee | $267,650.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $174,803.31 |
| Travel and Lodging | $5,833.88 |
| Food and Beverage | $4,612.89 |
| Entertainment | $218.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $1,526,540.39 | 2019-2023 | Xlif, Modulus, Pulse |
| Zimmer Biomet Holdings, INC. | $400,562.87 | 2019-2020 | |
| Highridge Medical LLC | $315,686.78 | 2024-2025 | Polaris 4.75 Spinal System, Spine-None, Trelloss-C Sa |
| Globus Medical, INC. | $263,252.27 | 2022-2025 | Xlif, Modulus, Modulus |
| Zimvie INC. | $31,900.34 | 2022-2023 | |
| Medtronic, INC. | $7,800.28 | 2021-2025 | Cd Horizon Spinal System, Catalyft Pl Expandable Interbody System, Zevo Anterior Cervical Plate System |
| Alphatec Spine, INC | $2,827.31 | 2022-2025 | Other - Miscellaneous, Lif, Invictus Open |
| Stryker Corporation | $2,171.23 | 2019-2025 | Na |
| Abbvie INC. | $389.83 | 2022-2023 | |
| Curiteva, INC. | $360.64 | 2023-2024 | |
| Mml US, INC. | $321.42 | 2022-2023 | Reactiv8 |
| Teva Pharmaceuticals USA, INC. | $264.86 | 2022-2023 | Ajovy, Austedo Xr, Austedo |
| Monteris Medical Corporation | $185.00 | 2025 | Neuroblate |
| Si-Bone, INC. | $138.46 | 2023 | |
| Upsher-Smith Laboratories LLC | $135.73 | 2022-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $124.95 | 2020 | |
| Janssen Pharmaceuticals, INC | $104.82 | 2022-2023 | Spravato |
| Neurocrine Biosciences, INC. | $97.16 | 2022-2023 | Ongentys, Ingrezza |
| Collegium Pharmaceutical, INC. | $93.54 | 2022-2023 | Belbuca |
| Alnylam Pharmaceuticals INC. | $85.03 | 2022-2023 | Amvuttra |
| Impel Pharmaceuticals INC. | $69.62 | 2023 | Trudhesa |
| Axsome Therapeutics, INC. | $57.52 | 2023 | Auvelity, Sunosi |
| Augmedics INC. | $43.97 | 2023 | Xvision |
| Lilly USA, LLC | $38.52 | 2023 | Amyvid, Emgality |
| Averitas Pharma INC. | $37.50 | 2023 | Qutenza |
| Amgen INC. | $30.70 | 2023 | Aimovig |
| Otsuka America Pharmaceutical, INC. | $20.79 | 2023 | Nuedexta |
| Sk Life Science, INC. | $20.78 | 2023 | |
| Pfizer INC. | $20.20 | 2023 | |
| Argenx US, INC. | $17.49 | 2022 | |
| Tanabe Pharma America, INC. | $16.46 | 2022 | |
| Abbott Laboratories | $16.03 | 2023 | Eterna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$657,596.70 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Kanter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.